Comparable stake leader
T. Rowe Price Investment Management, Inc.
SEC ownership of Ascendis Pharma A/S
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001612042.
Disclosed value leader
T. Rowe Price Investment Management, Inc.
Comparable rows
6/50
Latest evidence
30 Sep 2026
- Public ticker
- ASND on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
T. Rowe Price Investment Management, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
T. Rowe Price Investment Management, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001612042
- Issuer location
- Hellerup
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Ascendis Pharma A/S (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
T. Rowe Price Investment ...
Disclosed value leader
T. Rowe Price Investment ...
Comparable rows
6/50
Latest evidence
30 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
44 rows are not safely comparable across share classes.
13D/G row: T. Rowe Price Investment Management, Inc.
Showing 1-8 of 50 holder rows.
Quick read
T. Rowe Price Investment Management, Inc. leads the comparable SEC ownership view at 10%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens T. Rowe Price Investment Management, Inc.'s linked filing trail.
Comparable ownership
Top 5
T. Rowe Price Investment Manageme...
10%
WESTFIELD CAPITAL MANAGEMENT CO LP
8.5%
Janus Henderson Group Ltd.
6%
FMR LLC
5.2%
Artisan Partners Limited Partnership
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13D/G
|
10%
Reported 13D/G
· 30 Apr 2026
|
$1,617,120,732
6,506,219 shares
|
+$954,097,949 | 30 Apr 2026 |
| WESTFIELD CAPITAL MANAGEMENT CO LP |
13F
13D/G
Company · Westfield Capital Management Company, L.P.
|
8.5%
Reported 13D/G
· 31 Dec 2025
|
$1,167,634,813
5,125,027 shares
|
— | 30 Sep 2026 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
6%
Reported 13D/G
· 31 Mar 2026
|
$924,469,795
3,719,452 shares
|
-$150,026,520 | 31 Mar 2026 |
| FMR LLC |
13D/G
|
5.2%
Reported 13D/G
· 30 Sep 2026
|
$777,700,520
3,425,993 shares
|
$0 | 30 Sep 2026 |
| Artisan Partners Limited Partnership |
13D/G
13F
Artisan Partners Asset Management Inc. · Company
|
4.2%
Reported 13D/G
· 30 Jun 2026
|
$698,595,845
2,634,024 shares
|
$0 | 30 Jun 2026 |
| Capital International Investors |
13D/G
13F
Company
|
3.2%
Reported 13D/G
· 31 Mar 2026
|
$492,207,917
2,013,285 shares
|
-$267,935,411 | 31 Mar 2026 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
Company
|
—
denominator unverified
|
$431,925,066
1,896,095 shares
|
— | 30 Sep 2026 |
| FRANKLIN TEMPLETON INC |
13F
Company
|
—
denominator unverified
|
$285,862,787
1,108,296 shares
|
— | 30 Sep 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$4,736,859.
Buys
$777,066
Insiders: 2
Sells
$5,513,926
Insiders: 3
Net
-$4,736,859
Shares: -19,446
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 3,250
Shares: 22,696
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 3,236 | $0 | $872,905 | -$872,905 |
| 3-6 | 3,250 | 0 | $777,066 | $0 | +$777,066 |
| 6-9 | 0 | 19,460 | $0 | $4,641,021 | -$4,641,021 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Ascendis Pharma A/S. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Jan Moller Mikkelsen
Net 12M change
-$4.74M
Full value: -$4,736,859 · USD · 12-month changeLatest report
08 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jan Moller Mikkelsen | Director | $106,545,170 | Mixed | 18 Mar 2026 | ||
| Kennett Sprogoe | EVP & Head of Research & Product Development | $4,598,753 | Mixed | 18 Mar 2026 | ||
| Anni Lotte Kirstine Sonderbjerg Pedersen | EVP & Chief Admin Officer | $4,572,905 | Mixed | 18 Mar 2026 | ||
| Lars Holtug | Director | $1,056,518 | -$62,335 | -5.6% | Filing P/S | 02 Sep 2026 |
| Scott Thomas Smith | EVP & Chief Financial Officer | $956,373 | +$77,730 | +8.8% | Filing P/S | 02 Jun 2026 |
| Albert Cha | Director | $876,512 | Mixed | 18 Mar 2026 | ||
| Jean Jacques Bienaime | Director | $716,039 | +$699,337 | +4187% | Filing P/S | 14 Aug 2026 |
| Siham Imani | Director | $544,471 | Mixed | 18 Mar 2026 | ||
| William Fairey | Director | $497,473 | Mixed | 18 Mar 2026 | ||
| Lisa Bright Morrison | Director | $369,404 | Mixed | 18 Mar 2026 | ||
| Jay Donovan Wu | EVP & President US Market | $250,969 | Mixed | 18 Mar 2026 | ||
| Aimee Shu | EVP & Chief Medical Officer | $0 | Mixed | 18 Mar 2026 | ||
| Mads Bodenhoff | Svp & Pao | $0 | -$810,570 | -100% | Mixed | 08 Sep 2026 |
| Flemming Steen Jensen | EVP & Product Supply and Quality | $0 | -$4,641,021 | -100% | Mixed | 11 May 2026 |
| Michael Wolff Jensen | EVP, Chief Legal Officer | Mixed | 18 Mar 2026 |
Recent insider transactions for Ascendis Pharma A/S
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mads Bodenhoff | ASND | Ordinary Shares | Sale | -100% | -$810,570 | $270.19 | -3,000 | 0 | 08 Sep 2026 | Direct |
| Mads Bodenhoff | ASND | Ordinary Shares | Options Exercise | 3,000 | 3,000 | 08 Sep 2026 | Direct | |||
| Mads Bodenhoff | ASND | Warrants | Options Exercise | -81.4% | -3,000 | 687 | 08 Sep 2026 | Direct | ||
| Lars Holtug | ASND | Ordinary Shares | Sale | -5.57% | -$62,335 | $264.13 | -236 | 4,000 | 02 Sep 2026 | Direct |
| Jean J. Bienaime | ASND | Ordinary Shares | Purchase | 222.2% | $492,654 | $246.33 | 2,000 | 2,900 | 14 Aug 2026 | Direct |
| Scott Thomas Smith | ASND | Ordinary Shares | Purchase | 2.34% | $21,900 | $219.00 | 100 | 4,367 | 02 Jun 2026 | Direct |
| Jean J. Bienaime | ASND | Ordinary Shares | Purchase | 125% | $111,562 | $223.12 | 500 | 900 | 29 May 2026 | Direct |
| Scott Thomas Smith | ASND | Ordinary Shares | Purchase | 6.22% | $55,830 | $223.32 | 250 | 4,267 | 29 May 2026 | Direct |
| Jean J. Bienaime | ASND | Ordinary Shares | Purchase | $95,120 | $237.80 | 400 | 400 | 26 May 2026 | Direct | |
| Flemming Steen Jensen | ASND | Ordinary Shares | Sale | -100% | -$4,641,021 | $238.49 | -19,460 | 0 | 11 May 2026 | Direct |
| Jean J. Bienaime | ASND | Warrants | Award | 9,160 | 9,160 | 14 Apr 2026 | Direct | |||
| Jean J. Bienaime | ASND | Warrants | Disposed to Issuer | -100% | -9,160 | 0 | 14 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.